[HTML][HTML] Treatment of evolving cancers will require dynamic decision support
Highlights•Cancer is a heterogeneous and evolving disease, yet most drugs are
administered to simply give the maximum dose.•Treatment scheduling currently ignores the …
administered to simply give the maximum dose.•Treatment scheduling currently ignores the …
Group behavior and emergence of cancer drug resistance
Drug resistance is a major impediment in cancer. Although it is generally thought that
acquired drug resistance is due to genetic mutations, emerging evidence indicates that …
acquired drug resistance is due to genetic mutations, emerging evidence indicates that …
Path to clonal theranostics in luminal breast cancers
N Hajjaji, S Aboulouard, T Cardon, D Bertin… - Frontiers in …, 2022 - frontiersin.org
Integrating tumor heterogeneity in the drug discovery process is a key challenge to tackle
breast cancer resistance. Identifying protein targets for functionally distinct tumor clones is …
breast cancer resistance. Identifying protein targets for functionally distinct tumor clones is …
Resource-effective exploration of tumor treatments with multi-scale simulations
Machine learning is regularly used to interpret and analyze information from large and
complex datasets originating from numerous fields. In Bioinformatics, the exploration of …
complex datasets originating from numerous fields. In Bioinformatics, the exploration of …
[PDF][PDF] Evaluation of machine learning algorithms for the discovery of tumor treatments
V Stavropoulos - 2022 - dspace.lib.ntua.gr
Περίληψη Η τεχνητή νοη οσύνη χρησι οποιείται συχνά για να ερ ηνεύσει και να αναλύσει
εγάλους όγκους περίπλοκων δεδο ένων από διάφορα γνωστικά πεδία. Σε ένα από αυτά, την …
εγάλους όγκους περίπλοκων δεδο ένων από διάφορα γνωστικά πεδία. Σε ένα από αυτά, την …
Path to drugging functional clones of luminal breast cancers using in-depth proteomics with spatially resolved mass spectrometry guided by MALDI imaging
N Hajjaji, S Aboulouard, T Cardon, D Bertin, YM Robin… - medRxiv, 2021 - medrxiv.org
Integrating tumor heterogeneity in the drug discovery process is a key challenge to tackle
breast cancer resistance. Identifying protein targets for functionally distinct tumor clones is …
breast cancer resistance. Identifying protein targets for functionally distinct tumor clones is …